SCHEMBL8002000

SCHEMBL8002000

Cc1[nH]cnc1-c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.61
CYP3A4 P08684 1/20 0.61
MAPT P10636 1/20 0.61
ADORA3 P0DMS8 2/20 0.45
ADORA2A P29274 2/20 0.45
ADORA1 P30542 2/20 0.45
CCNB2 O95067 1/20 0.45
CDK1 P06493 1/20 0.45
CCNB1 P14635 1/20 0.45
CCNA2 P20248 1/20 0.45
CDK2 P24941 1/20 0.45
CCNA1 P78396 1/20 0.45
CDK5 Q00535 1/20 0.45
CDK5R1 Q15078 1/20 0.45
CCNB3 Q8WWL7 1/20 0.45
IDO1 P14902 4/20 0.43
HPGD P15428 2/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22434856 0.83 ADORA3 (0.50) KDM4ECYP3A4MAPTADORA3ADORA2A
SCHEMBL7295129 0.81 MAPK14 (0.51) KDM4ECYP3A4MAPTCCNB2CDK1
Lofemizole SCHEMBL35441 0.79 ADORA3 (0.47) KDM4ECYP3A4MAPTADORA3ADORA2A
SCHEMBL21428970 0.79 MAPK14 (0.54) KDM4ECYP3A4MAPTSMN1; SMN2MAPK14
SCHEMBL3141937 0.79 ASIC3 (0.41) KDM4ECYP3A4MAPTADORA3ADORA1
SCHEMBL2691682 0.79 CYP2A6 (0.56) KDM4ECYP3A4MAPTIDO1HPGD
Lofemizole SCHEMBL44549 0.78 SMN1; SMN2 (0.47) KDM4ECYP3A4MAPTADORA3ADORA2A
SCHEMBL224770 0.76 KDM4E (1.00) KDM4ECYP3A4MAPTADORA3ADORA2A
SCHEMBL21400340 0.74 KDM4E (0.67) KDM4ECYP3A4MAPTADORA3ADORA2A
SCHEMBL544140 0.74 KDM4E (0.61) KDM4ECYP3A4MAPTADORA3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115490668-A Pyrimidyl imidazole compound, preparation method thereof and organic weldable protective agent 深圳市贝加电子材料有限公司 2022-12-20 CN claimed
CN-100572362-C A kind of diphenyl-imidazole compound and preparation method thereof DONGSHUO SCIENCE AND TECHNOLOG (CN) 2009-12-23 CN claimed
CN-1944414-A Diphenyl-imidazole compound and its preparing method DONGHUO SCIENCE AND TECHNOLOGY (CN) 2007-04-11 CN claimed
US-20250215572-A1 SURFACE TREATMENT AGENT FOR COPPER OR COPPER ALLOY SHIKOKU CHEMICALS CORPORATION (JP) 2025-07-03 US disclosed
EP-4506488-A1 SURFACE TREATMENT AGENT FOR COPPER OR COPPER ALLOY Shikoku Chemicals Corporation (JP) 2025-02-12 EP disclosed
CN-115490668-B Pyrimidylimidazole compound, preparation method thereof and organic solderability preservative 深圳市贝加电子材料有限公司 2024-04-02 CN disclosed
WO-2023190263-A1 SURFACE TREATMENT AGENT FOR COPPER OR COPPER ALLOY 四国化成工業株式会社 2023-10-05 WO disclosed
CN-115490668-A Pyrimidyl imidazole compound, preparation method thereof and organic weldable protective agent 深圳市贝加电子材料有限公司 2022-12-20 CN disclosed
EP-3559009-B1 COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY CALITHERA BIOSCIENCES INC (US) 2021-04-07 EP disclosed
EP-3770148-A1 RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF Beijing Tide Pharmaceutical Co., Ltd. (CN) 2021-01-27 EP disclosed
EP-3725785-A1 GLUTARIMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING GLUTARIMIDE DERIVATIVES Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) 2020-10-21 EP disclosed
US-20110046066-A1 INHIBITORS OF IAP GENENTECH, INC. (US) 2011-02-24 US disclosed
CN-100572362-C A kind of diphenyl-imidazole compound and preparation method thereof DONGSHUO SCIENCE AND TECHNOLOG (CN) 2009-12-23 CN disclosed
CN-100572362-C A kind of diphenyl-imidazole compound and preparation method thereof DONGSHUO SCIENCE AND TECHNOLOG (CN) 2009-12-23 CN disclosed
CN-1944414-A Diphenyl-imidazole compound and its preparing method DONGHUO SCIENCE AND TECHNOLOGY (CN) 2007-04-11 CN disclosed
US-7202381-B2 Compounds as opioid receptor modulators JANSSEN PHARMACEUTICA, NV (BE) 2007-04-10 US disclosed
WO-2006114371-A1 NOVEL COMPOUNDS FOR TREATING INFLAMMATORY DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-11-02 WO disclosed
US-6043254-A ANTIPROLIFERATIVE AGENT; ENZYME INHIBITOR BOEHRINGER INGELHEIM PHARMA KG (DE) 2000-03-28 US disclosed
WO-1999051590-A1 SUBSTITUTED INDOLINONES AS KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMA KG (DE) 1999-10-14 WO disclosed
CN-1060466-A Derivatives of Benzene, Pyridine and Pyrimidine EISAI CO LTD (JP) 1992-04-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046066-A1 INHIBITORS OF IAP BIRC5, XIAP, BIRC3 KDM4E 2867/4885CYP3A4 4832/4885MAPT 2711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.